The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
Portfolio Pulse from Benzinga Insights
Thirteen analysts have recently published ratings on Regeneron Pharmaceuticals (NASDAQ:REGN), with a mix of bullish, somewhat bullish, indifferent, and somewhat bearish sentiments. The average 12-month price target is $1069.69, reflecting a slight increase from the previous average. Key analysts have maintained or raised their ratings and price targets, indicating a generally positive outlook despite some financial challenges.
June 24, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Thirteen analysts have provided a range of ratings for Regeneron Pharmaceuticals, with a generally positive outlook. The average 12-month price target has increased slightly to $1069.69. Key analysts have maintained or raised their ratings and price targets, indicating confidence in the company's future performance despite some financial challenges.
The majority of analysts have maintained or raised their ratings and price targets for Regeneron Pharmaceuticals, indicating a positive sentiment. The slight increase in the average 12-month price target suggests confidence in the company's future performance. However, the company faces some financial challenges, such as a decline in revenue growth and a below-average ROE.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100